Intellia vs Beam Therapeutics vs Prime Medicine
Intellia, Beam Therapeutics, and Prime Medicine represent three distinct gene editing modalities — CRISPR-Cas9, base editing, and prime editing respectively — each with different clinical maturity, risk profiles, and market valuations. By March 2026, all three have achieved landmark clinical milestones: Intellia's lonvo-z completed Phase 3 enrollment, Beam achieved the first clinical genetic correction, and Prime Medicine published first-in-human prime editing results in the NEJM. This three-way comparison pits an in vivo CRISPR leader against the base editing pioneer and the newest entrant in precision editing.
Last updated: March 30, 2026
Intellia & Beam (Established Editing Platforms)
Intellia ($1.5B market cap) leads in vivo CRISPR-Cas9 editing via LNP delivery, with lonvo-z Phase 3 complete and BLA target H2 2026. Beam ($2.8B) leads base editing with the first clinical genetic correction (BEAM-302) and a BLA-track SCD program (BEAM-101). Together they represent the more clinically advanced gene editing platforms.
Prime Medicine (Prime Editing)
Prime Medicine ($600M market cap) is the clinical-stage leader in prime editing — the most versatile gene editing tool that can make all 12 base changes plus insertions and deletions without double-strand breaks or bystander editing. Its NEJM-published PM359 data showed 69-83% gene correction in CGD patients.
Key Specifications
| Feature | Intellia & Beam (Established Editing Platforms) | Prime Medicine (Prime Editing) |
|---|---|---|
| Intellia ticker / market cap | NTLA / ~$1.5B | — |
| Beam ticker / market cap | BEAM / ~$2.8B | — |
| Intellia lead program | Lonvo-z (NTLA-2002) — HAE, Phase 3 complete, BLA H2 2026 | — |
| Beam lead program | BEAM-101 (risto-cel) — SCD, BLA targeted YE 2026 | — |
| Intellia editing approach | In vivo CRISPR-Cas9 + LNP delivery | — |
| Beam editing approach | Base editing (ABE + CBE), ex vivo + in vivo | — |
| Intellia key data | 97% attack-free at 3 years (lonvo-z); 93% TTR knockdown (nex-z) | — |
| Beam key data | First clinical genetic correction (BEAM-302, AATD) | — |
| Combined clinical trials | ~10+ active programs | — |
| Nearest approval | Lonvo-z or BEAM-101 — both targeting BLA 2026 | — |
| Ticker / market cap | — | PRME / ~$600M |
| Lead clinical program | — | PM359 — CGD, Phase 1/2 (winding down — too rare) |
| Key upcoming IND | — | PM577 — Wilson's Disease (H1 2026) |
| Editing approach | — | Prime editing (reverse transcriptase + Cas9 nickase + pegRNA) |
| Key clinical data | — | 69-83% gene correction in CGD patients (NEJM, Dec 2025) |
| Disease mutation coverage | — | ~89% of known disease-causing mutations |
| Efficiency milestone | — | PE7: 21x improvement; PE7+AI: 18.8x over PEmax |
| Key partnerships | — | Bristol Myers Squibb (CAR-T), CF Foundation ($39M) |
| Cash position | — | ~$300M (runway into 2027) |
| Key advantage | — | Most versatile and precise editing — no bystander, no RNA off-targets |
Intellia & Beam (Established Editing Platforms)
Advantages
- Intellia lonvo-z Phase 3 HAELO enrollment completed in 9 months — 97% of patients attack-free at 3 years
- Intellia nex-z: 93% TTR knockdown sustained 3+ years, Breakthrough Therapy Designation for ATTR-CM
- Beam BEAM-302: first-ever clinical genetic correction of a disease-causing point mutation (AATD, March 2025)
- Beam BEAM-101 for SCD: 30 patients dosed, FDA RMAT designation, BLA targeted year-end 2026
- Massive pharma validation: Beam secured Pfizer ($300M) + Lilly ($200M) deals in 2025
Limitations
- Intellia stock severely depressed (~$12) — may need financing before commercialization ($605M cash)
- Intellia MAGNITUDE trial (nex-z, ATTR-CM) had FDA clinical hold — now lifted but delayed
- Beam's base editing limited to 4 of 12 possible transitions (C→T, G→A, A→G, T→C)
- Both still pre-approval — no product revenue (Beam has $139.7M collaboration revenue)
- In vivo CRISPR (Intellia) and in vivo base editing both currently limited to liver targets via LNP
Prime Medicine (Prime Editing)
Advantages
- NEJM-published first-in-human prime editing: PM359 achieved 69% and 83% gene correction in CGD patients (Dec 2025)
- Most versatile editing platform: all 12 transitions/transversions + insertions + deletions — corrects ~89% of disease mutations
- Zero bystander editing and zero RNA off-targets — highest precision of any clinical editing tool
- PE7 efficiency revolution: 21-fold improvement (Nature 2024); AI-enhanced PE7 reaches 18.8x over PEmax (Cell 2025)
- Bristol Myers Squibb partnership for prime-edited CAR-T; CF Foundation $39M grant
Limitations
- Smallest market cap (~$600M) — highest financial risk and most likely to need additional capital
- Winding down CGD program despite strong efficacy — disease too rare for commercial viability
- Earlier clinical stage than Intellia or Beam — PM577 (Wilson's) IND targeted H1 2026
- In vivo prime editing not yet demonstrated in humans — preclinical LNP delivery shows ~10-20% efficiency in mouse liver
- Larger protein complex (~6.3 kb) creates delivery challenges vs. smaller base editors or Cas9
The Verdict
These three companies represent a risk-reward spectrum across gene editing modalities. Intellia ($1.5B) offers the highest near-term upside — if lonvo-z is approved, it becomes the first in vivo CRISPR therapy, potentially a transformative milestone for the field, at a deeply discounted valuation. Beam ($2.8B) is the most de-risked play with $500M+ in pharma deals, a BLA-track program, and the first clinical genetic correction validating base editing. Prime Medicine ($600M) is the highest-risk, highest-reward bet — prime editing is objectively the most powerful editing tool (89% disease coverage, zero bystander editing, NEJM-published 69-83% correction), but the company is earlier-stage with a smaller cash runway. For investors, the key question is timeline: Intellia and Beam are 12-18 months from potential approvals, while Prime Medicine is 3-5 years away. For the field of genetic medicine, all three technologies are needed — CRISPR for gene knockout, base editing for precise transitions, and prime editing for everything else.
Sources & References
- [1]Intellia lonvo-z Phase 3 enrollment complete
- [2]Intellia lonvo-z 3-year data
- [3]Beam BEAM-302 first clinical correction
- [4]Beam BEAM-101 RMAT designation & BLA track
- [5]Prime Medicine PM359 NEJM publication
- [6]Prime Medicine FY2025 results & pipeline
- [7]PE7 efficiency (Nature 2024)
- [8]Beam-Pfizer and Beam-Lilly deals